Dear Sir,
The currently most promising treatments of haemophilia are gene therapy based on inactivated viral vectors and immunotherapy using a bispecific antibody mimicking the catalytic action of factor VIII (FVIII). Considering the past viral contamination of the haemophilia community and the persistent unavoidable and challenging development of neutralizing antibodies mainly against exogenous FVIII, it was not expected that viral vectors and antibodies would serve to develop and validate treating or curing approaches for patients with haemophilia. [ … ]



Catriona Mactier - Great Ormond Hospital for Children NHS Trust Haemophilia Centre, London, United Kingdom

Cedric Hermans - Division of Haematology, Haemophilia Centre, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belgium

  • Abstract viewed - 159 times
  • PDF downloaded - 27 times